Colleoni, M

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 8.

Journal Article

Francis, PA; Pagani, O; Fleming, GF; Walley, BA; Colleoni, M; Láng, I; Gómez, HL; Tondini, C; Ciruelos, E; Burstein, HJ; Bonnefoi, HR; Bellet, M; Martino, S; Geyer, Jr. CE; Goetz, MP; Stearns, V; Pinotti, G; Puglisi, F; Spazzapan, S; Climent, MA; ... (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England journal of medicine NEJM, 379(2), pp. 122-137. Massachusetts Medical Society MMS 10.1056/NEJMoa1803164

Gennari, A; Sun, Z; Hasler-Strub, U; Colleoni, M; Kennedy, M J; Von Moos, R; Cortés, J; Vidal, M J; Hennessy, B; Walshe, J; Amillano Parraga, K; Ribi, K; Bernhard, Jürg; Morales, S Murillo; Pagani, O; Barbeaux, A; Borstnar, S; Rabaglio, Manuela; Maibach, R; Regan, M M; ... (2018). A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of oncology, 29(3), pp. 661-668. Oxford University Press 10.1093/annonc/mdx772

Karlsson, P; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Collins, J; Murray, E; Zaman, K; Colleoni, M; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of oncology, 22(10), pp. 2216-26. Oxford: Oxford University Press 10.1093/annonc/mdq735

Colleoni, M; Sun, Z; Martinelli, G; Basser, R L; Coates, A S; Gelber, R D; Green, M D; Peccatori, F; Cinieri, S; Aebi, S; Viale, G; Price, K N; Goldhirsch, A (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of oncology, 20(8), pp. 1344-51. Oxford: Oxford University Press 10.1093/annonc/mdp024

Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J-M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology, 20(9), pp. 1489-98. Oxford: Oxford University Press 10.1093/annonc/mdp033

Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, J F; Aebi, S; Yeo, W; Thürlimann, B; Green, M D; Colleoni, M; Gelber, R D; Castiglione-Gertsch, M; Price, K N; Goldhirsch, A; Coates, A S (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer, 98(1), pp. 25-33. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604092

Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thürlimann, B; Mendiola, C; Aebi, S; Price, K N; Pagani, O; Simoncini, E; Castiglione Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology, 18(4), pp. 701-8. Oxford: Oxford University Press 10.1093/annonc/mdl492

Colleoni, M; Gelber, S; Goldhirsch, A; Aebi, S; Castiglione-Gertsch, M; Price, KN; Coates, AS; Gelber, RD; International, Breast Cancer Study Group (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of clinical oncology, 24(9), pp. 1332-41. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.03.0783

This list was generated on Sun Aug 18 21:00:02 2019 CEST.
Provide Feedback